Aktis Oncology

The company’s platform-based discovery approach produces molecules that concentrate the power of alpha particles for delivery to solid tumors.

Nectin-4-Targeted Radiopharmaceutical, in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors

Aktis focuses on creating precision therapies to put solid cancer into remission.

Carlos Rodriguez is executive director of corporate development at Aktis Oncology, responsible for business development and corporate strategy for the company’s radiopharmaceutical portfolio.

Dane Wittrup is a scientific advisor to Aktis Oncology and a professor of chemical and biological engineering at the Massachusetts Institute of Technology. His research focuses on engineering biopharmaceutical proteins through directed evolution.

Erik Chelius is a scientific advisor to Aktis Oncology. He spent more than 20 years in development and manufacturing at Eli Lilly & Co. and joined Endocyte in 2012.

Johannes Czernin is a scientific advisor to Aktis Oncology, a professor at the David Geffen School of Medicine at UCLA, and chief of the Ahmanson Translational Theranostics Division at UCLA. He was named director of Nuclear Medicine in 1996.

The company lists locations in Boston, MA, at 17 Drydock Avenue, Suite #17-401, Boston, MA 02210, and Research Triangle Park, NC, at 801 Capitola Drive, Building 1, Durham, NC 27713.

Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care

Aktis Oncology’s privacy policy describes the website’s data collection and use practices and states that the company respects visitors’ privacy and is committed to protecting personal information.

Aktis Oncology provides its website subject to the terms and conditions in its Terms of Service agreement.